Tag Archives: demcizumab

April, 2017

10 April
OncoMed’s Demcizumab Misses Primary Endpoint in Mid-Stage Pancreatic Cancer Trial

REDWOOD CITY, Calif., April 10, 2017 (GLOBE NEWSWIRE) — OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today reported top-line results from the company’s Phase 2 YOSEMITE clinical trial of demcizumab (anti-DLL4, OMP-21M18) in combination with Abraxane® (paclitaxel …
Share

2 April
OncoMed to Investigate the Combination of its Experimental Cancer Drug with Lilly’s Alimta in Lung Cancer

OncoMed Pharmaceuticals, Inc. has teamed up with Eli Lilly and Company to test a combination of the companies’ drugs for treatment of lung cancer. The companies announced that they have entered into an agreement, under which OncoMed’s anti-DLL4 antibody, demcizumab, is being tested in combination with Lilly’s lung cancer drug, …
Share